Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics : Minocycline Products Cleared for Commercial Sale in Medical Tourism Pilot Zone in China

08/02/2021 | 10:59am EDT


© MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
09/08VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conferen..
AQ
09/03VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/18INSIDER TRENDS : Selling By Insiders Lingers at VYNE Therapeutics
MT
08/17INSIDER TRENDS : Insider Sales Add to 90-Day Trend at VYNE Therapeutics
MT
08/16INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at VYNE Therapeutics
MT
08/13VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From..
MT
08/12VYNE THERAPEUTICS : Explanatory Note (Form 8-K)
PU
08/12VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial S..
AQ
08/12VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8..
AQ
08/12VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 18,2 M - -
Net income 2021 -70,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,17x
Yield 2021 -
Capitalization 80,9 M 80,9 M -
Capi. / Sales 2021 4,43x
Capi. / Sales 2022 11,3x
Nbr of Employees 106
Free-Float 87,1%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,57 $
Average target price 6,67 $
Spread / Average Target 325%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-75.16%81
BIONTECH SE340.60%90 003
GILEAD SCIENCES, INC.22.91%89 434
REGENERON PHARMACEUTICALS34.93%67 910
WUXI APPTEC CO., LTD.35.75%65 728
VERTEX PHARMACEUTICALS-20.33%48 539